International audienceCancer is initiated by somatic mutations in oncogenes or tumor suppressor genes. However, additional alterations provide selective advantages to the tumor cells to resist treatment and develop metastases. Their identification is of paramount importance. Reduced expression of EFA6B (Exchange Factor for ARF6, B) is associated with breast cancer of poor prognosis. Here, we report that loss of EFA6B triggers a transcriptional reprogramming of the cell-to-ECM interaction machinery and unleashes CDC42-dependent collective invasion in collagen. In xenograft experiments, MCF10 DCIS.com cells, a DCIS-to-IDC transition model, invades faster when knocked-out for EFA6B. In addition, invasive and metastatic tumors isolated from pat...
Interleukin-6 (IL-6), involved in cancer-related inflammation, acts as an autocrine and paracrine gr...
L'homéostasie des tissus épithéliaux est fondamentale à la survie et au maintien d'un organisme sain...
Background: The ErbB2/Her2/Neu receptor tyrosine kinase is amplified in ~30 % of human breast cancer...
International audienceCancer is initiated by somatic mutations in oncogenes or tumor suppressor gene...
International audienceOne of the earliest events in epithelial carcinogenesis is the dissolution of ...
My PhD research project aims to demonstrate a novel negative regulatory pathway of breast cancer tum...
BACKGROUND: Eukaryotic Initiation factor 6 (eIF6) is a peculiar translation initiation factor that ...
Eukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formation. eIF6...
Cyr61, a member of the CCN family of genes, is an angiogenic factor. We have shown that it is overex...
Metastatic disease is the major cause of breast cancer–related death and despite many advances, curr...
SummaryEukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formatio...
AbstractNumerous studies by our lab and others demonstrate that epidermal growth factor receptor (EG...
Abstract Background Breast cancer (BC) is the leading cause of morbidity and the second leading caus...
Li M. and Ng S.M. are equal first authorsEFA6A, or Pleckstrin and Sec7 domain protein, is a member o...
Interleukin-6 (IL-6), involved in cancer-related inflammation, acts as an autocrine and paracrine gr...
Interleukin-6 (IL-6), involved in cancer-related inflammation, acts as an autocrine and paracrine gr...
L'homéostasie des tissus épithéliaux est fondamentale à la survie et au maintien d'un organisme sain...
Background: The ErbB2/Her2/Neu receptor tyrosine kinase is amplified in ~30 % of human breast cancer...
International audienceCancer is initiated by somatic mutations in oncogenes or tumor suppressor gene...
International audienceOne of the earliest events in epithelial carcinogenesis is the dissolution of ...
My PhD research project aims to demonstrate a novel negative regulatory pathway of breast cancer tum...
BACKGROUND: Eukaryotic Initiation factor 6 (eIF6) is a peculiar translation initiation factor that ...
Eukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formation. eIF6...
Cyr61, a member of the CCN family of genes, is an angiogenic factor. We have shown that it is overex...
Metastatic disease is the major cause of breast cancer–related death and despite many advances, curr...
SummaryEukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formatio...
AbstractNumerous studies by our lab and others demonstrate that epidermal growth factor receptor (EG...
Abstract Background Breast cancer (BC) is the leading cause of morbidity and the second leading caus...
Li M. and Ng S.M. are equal first authorsEFA6A, or Pleckstrin and Sec7 domain protein, is a member o...
Interleukin-6 (IL-6), involved in cancer-related inflammation, acts as an autocrine and paracrine gr...
Interleukin-6 (IL-6), involved in cancer-related inflammation, acts as an autocrine and paracrine gr...
L'homéostasie des tissus épithéliaux est fondamentale à la survie et au maintien d'un organisme sain...
Background: The ErbB2/Her2/Neu receptor tyrosine kinase is amplified in ~30 % of human breast cancer...